VERU - FDA advisory panel votes against Veru COVID-19 therapy sabizabulin in 8-5 tally
- Members of the FDA's Pulmonary-Allergy Drugs Advisory Committee voted 8-5 on Wednesday that the benefits of Veru's ( NASDAQ: VERU ) COVID-19 pill sabizabulin do not outweigh the risks.
- Veru ( VERU ) is seeking approval of the drug for hospitalized adults with COVID at high risk of acute respiratory distress syndrome.
- In briefing documents, FDA staff identified multiple uncertainties related to data from a study that the company used in its application.
For further details see:
FDA advisory panel votes against Veru COVID-19 therapy sabizabulin in 8-5 tally